Taysha Gene Therapies, Inc. (TSHA)
TSHA moved a median of -0.33% 30 minutes after news, and +0.79% by the close. How TSHA actually reacts to news — the realized, point-in-time move the market made, measured across 255 labeled events over the last three years with zero look-ahead.
TSHA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 253 |
| 30-min | -0.33% | 44% | 253 |
| 60-min | -0.22% | 46% | 253 |
| to close | +0.79% | 56% | 252 |
| Middle 50% of TSHA reactions | -2.18% to +1.72% |
|---|---|
| Median reaction (30-min) | -0.33% |
| Measured reactions | 255 |
Half of all Taysha Gene Therapies, Inc. news events land between -2.18% and +1.72% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TSHA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 18 | +0.19% | 83% | +0.55% |
| Rating reiterations | 123 | 0.00% | 49% | -0.12% |
| Price-target raises | 18 | +0.43% | 50% | -0.97% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how TSHA ranks against every other measured name →
That’s how TSHA usually reacts — get an email when it moves on news →Email me when TSHA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TSHA's baseline. Nothing else.
Recent TSHA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.83% | -3.54% | |
| Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting | Press release | GlobeNewswire | +0.72% | -2.47% | |
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.55% | +1.82% | |
| Form 10-Q Taysha Gene Therapies, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.98% | +5.87% | |
| Form 8-K Taysha Gene Therapies, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +1.98% | +5.87% | |
| Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.98% | +5.87% | |
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.62% | +1.71% | |
| Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 | Press release | GlobeNewswire | +0.08% | +2.70% | |
| Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome | Press release | GlobeNewswire | -2.12% | -1.87% | |
| Form 8-K Taysha Gene Therapies, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +1.31% | +3.76% | |
| Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting | Press release | GlobeNewswire | +1.31% | +3.76% | |
| Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -6.51% | -9.08% | |
| Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -6.51% | -9.08% | |
| Form 8-K Taysha Gene Therapies, For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +1.54% | +0.46% | |
| Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome | Press release | GlobeNewswire | +1.54% | +0.46% | |
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.17% | -6.14% | |
| Form 8-K Taysha Gene Therapies, For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -1.06% | -2.29% | |
| Form 10-Q Taysha Gene Therapies, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.08% | +5.60% | |
| Form 8-K Taysha Gene Therapies, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | +5.60% | |
| Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.08% | +5.60% | |
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.37% | +4.90% | |
| Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 | Press release | GlobeNewswire | +0.80% | +0.32% | |
| Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting | Press release | GlobeNewswire | +0.53% | -4.11% | |
| Form ARS Taysha Gene Therapies, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.94% | +5.66% | |
| Form DEF 14A Taysha Gene Therapies, For: Jun 01 | SEC filing · Form DEF | SEC EDGAR | -0.94% | +5.66% | |
| Form DEFA14A Taysha Gene Therapies, | SEC filing · Form DEFA14A | SEC EDGAR | -0.94% | +5.66% | |
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.69% | +4.03% | |
| Form 10-K Taysha Gene Therapies, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.52% | +0.22% | |
| Form 8-K Taysha Gene Therapies, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -3.52% | +0.22% | |
| Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -3.52% | +0.22% | |
| Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 | Press release | GlobeNewswire | +1.13% | +4.54% | |
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.69% | +4.58% | |
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.30% | +0.22% | |
| Form S-8 Taysha Gene Therapies, | SEC filing · Form S-8 | SEC EDGAR | +2.45% | +0.00% | |
| Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome | Press release | GlobeNewswire | +1.24% | +8.45% | |
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.13% | +6.45% | |
| Form 10-Q Taysha Gene Therapies, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.29% | -0.47% | |
| Form 8-K Taysha Gene Therapies, For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -6.29% | -0.47% | |
| Form S-3ASR Taysha Gene Therapies, | SEC filing · Form S-3ASR | SEC EDGAR | -6.29% | -0.47% | |
| Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -6.29% | -0.47% | |
| Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 | Press release | GlobeNewswire | +2.66% | +2.04% | |
| Form 8-K Taysha Gene Therapies, For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | -2.45% | -3.67% | |
| Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome | Press release | GlobeNewswire | -2.45% | -3.67% | |
| Form 8-K Taysha Gene Therapies, For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | -0.20% | -2.34% | |
| Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting | Press release | GlobeNewswire | -0.20% | -2.34% | |
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -3.09% | -9.61% | |
| Form 8-K Taysha Gene Therapies, For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | +5.97% | +21.39% | |
| Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Press release | GlobeNewswire | +5.97% | +21.39% | |
| Rett Syndrome Research Trust Expands Internal Team to Speed the Advancement of Genetic Medicine Cures for Rett Syndrome | Press release | PR Web | +0.00% | +4.14% | |
| Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.97% | +1.82% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TSHA section they belong to.
Where else TSHA is measured.
TSHA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Taysha Gene Therapies, Inc.'s median reaction calculated?
Every labeled TSHA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 255 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of TSHA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TSHA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.